Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
Freiburg, Germany, September 14, 2021
Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce sufficient quantities of factor H to cover all three clinical phases.
Eleva has ordered four more state-of-the-art, 500 l single-use reactors with improved LED technology from Sartorius Stedim Systems GmbH. The scale-up will enable Eleva to enter clinical development of factor H, a key component of a pathway of the immune system known as alternative complement pathway.
The complement system enhances (complements) the body’s ability to clear microbes and damaged cells from an organism. Factor H regulates the activation of that immune response and ensures the body’s own cells are protected. Insufficient regulation of the complement system leads to excessive inflammation and potential tissue damage.
Factor H is a complex protein that only Eleva’s moss-based platform has thus far been able to yield in highest – human-like – quality. Eleva has been able to demonstrate a significant reduction in tissue damage and inflammation in animal models when its recombinant factor H was supplemented.
Based in Freiburg, Germany, Eleva develops novel biological therapies with its pharmaceutical partners. The privately-held company leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins. Eleva has successfully developed drug candidates into clinical phases.